Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Nov;3(11):e454.
doi: 10.1371/journal.pmed.0030454.

Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection

Inge Derdelinckx  1 , Mark A Wainberg, Joep M A Lange, Andrew Hill, Yasmin Halima, Charles A B Boucher
Affiliations
Review

Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection

Inge Derdelinckx et al. PLoS Med. 2006 Nov.

Abstract

The authors formulate criteria for an optimal pre-exposure prophylaxis drug candidate, and evaluate existing antiviral drug classes for their suitability.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: ID received travel grants from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Roche. MAW declares that he has no competing interests. JAL declares that he has received honoraria for advice, speaking engagements, or research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche, and Tibotec. AH has received consultancy payments from Tibotec (Johnson and Johnson). YH received a travel grant to participate in a GlaxoSmithKline advisory board. CABB serves or has served on scientific (HIV) advisory boards, spoken at symposia of, and/or received research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Roche. He declares that he does not own any pharmaceutical company stock. He is a grant holder of various European Community grants for the study of HIV drug resistance and drug resistance transmission. He also serves as a member of the World Health Organization HIV ResNet advisory body and is a member of organising committees of several meetings on HIV.

Figures

Figure 1
Figure 1. Cost-Effectiveness of PREP with a 40% Efficacy Rate
This graph shows the cost per infection avoided by PREP (US$) by annual HIV incidence (%) and by cost of PREP treatment (US$), assuming PREP cuts incidence of HIV infection by 40%. The striped bars indicate that the cost per infection avoided by PREP was over $10,000 and was therefore not considered to be cost-effective.
Figure 2
Figure 2. Cost-Effectiveness of PREP with an 80% Efficacy Rate
This graph shows the cost per infection avoided by PREP (US$) by annual HIV incidence (%) and by cost of PREP treatment (US$), assuming PREP cuts incidence of HIV infection by 80%. The striped bars indicate that the cost per infection avoided by PREP was over $10,000 and was therefore not considered to be cost-effective.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shelton JD, Halperin DT, Wilson D. Has global incidence peaked? Lancet. 2006;367:1120–1122. - PubMed
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med. 2005;2:e298. doi: 10.1371/journal.pmed.0020298. - DOI - PMC - PubMed
    1. Gray R, Wawer MJ, Thoma M, Serwadda D, Nalugoda F Male circumcision and the risks of female HIV and sexually transmitted infection acquisition in Rakai, Uganda. 2006. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, United States of America. Available: http://www.retroconference.org/2006/Abstracts/25977.HTM. Accessed 4 October 2006.
    1. Dhawan D, Mayer KH. Microbicides to prevent HIV transmission: Overcoming obstacles to chemical barrier protection. J Infect Dis. 2006;193:36–44. - PubMed
    1. Tsai C-C, Emau P, Jiang Y, Tian B, Morton WR, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses. 2003;19:535–541. - PubMed

Publication types

MeSH terms